Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacotherapy of type 2 diabetes: An update and future directions.
DeMarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. DeMarsilis A, et al. Among authors: reddy n. Metabolism. 2022 Dec;137:155332. doi: 10.1016/j.metabol.2022.155332. Epub 2022 Oct 12. Metabolism. 2022. PMID: 36240884 Review.
Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).
Ho K, Hoesley C, Anderson PL, Fernández-Romero JA, Friedland BA, Kelly CW, Jiao Y, Edick S, Brand R, Kunjara Na Ayudhya RP, Zyhowski A, Hartman DJ, Reddy NB, Al-Khouja A, Piper J, Bauermeister JA, Teleshova N, Melo C, Cornejal N, Barnable P, Singh D, Scheckter R, McClure T, Hillier SL, Hendrix CW; MTN-037 Study Team. Ho K, et al. Among authors: reddy nb. J Acquir Immune Defic Syndr. 2024 Dec 1;97(4):379-386. doi: 10.1097/QAI.0000000000003506. J Acquir Immune Defic Syndr. 2024. PMID: 39808074 Clinical Trial.
Facile Synthesis of Oxazolidinones as Potential Antibacterial Agents.
Els SP, Govender KB, Sokhela MK, Bhatt N, Reddy N, Kruger HG, Arvidsson PI, Gunosewoyo H, Govender T, Naicker T. Els SP, et al. Among authors: reddy n. ChemistryOpen. 2025 Jan 7:e202400432. doi: 10.1002/open.202400432. Online ahead of print. ChemistryOpen. 2025. PMID: 39776351 Free article.
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.
Maharaj N, Uppada DR, Reddy N, Reddy P, Batalov A, Lvanova D, Staykova N, Baranauskaite A, Hassan LA. Maharaj N, et al. Among authors: reddy n. Arthritis Res Ther. 2024 Dec 21;26(1):225. doi: 10.1186/s13075-024-03456-w. Arthritis Res Ther. 2024. PMID: 39709462 Free PMC article. Clinical Trial.
1,559 results